Head And Neck: Phase 1: NKG2A inhibitor: CA047004

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Title
Bristol-Myers Squibb CA047004 (Phase 1 NKG2A inhibitor- Head and Neck)
Study Title

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Site Link
Malignancy
Head and neck cancer (SCCHN), laryngeal, hypopharyngeal, oropharyngeal, oral cavity, oropharynx, hypopharynx, larynx
Stage
Disease Setting
ADVANCED/METASTATIC
Line Of Therapy
> or = 2nd line
Investigational Agent
BMS-986315 with either nivolumab or cetuximab
Drug Class
NKG2A inhibitor
PI
Dan Vaena, MD
Sponsor
Bristol-Myers Squibb
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • SCCHN
  • Must have received prior PD-1 or PD-L1 inhibitor
  • ECOG PS 0-1
  • No known autoimmune disease
  • No need for steroids or other immunsuppressive medicine
  • No interstitual lung disease or pulmonary fibrosis
Objective
  • Primary- 
    • AEs
    • SAEs
    • Number of deaths
  • Secondary
    • ORR
    • DoR
    • PFS
    • PK
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
squamous cell carcinoma
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X